239 related articles for article (PubMed ID: 35280813)
41. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
42. Clinically significant prostate cancer detection on MRI: A radiomic shape features study.
Cuocolo R; Stanzione A; Ponsiglione A; Romeo V; Verde F; Creta M; La Rocca R; Longo N; Pace L; Imbriaco M
Eur J Radiol; 2019 Jul; 116():144-149. PubMed ID: 31153556
[TBL] [Abstract][Full Text] [Related]
43. A nomogram based on PI-RADS v2.1 and clinical indicators for predicting clinically significant prostate cancer in the transition zone.
Wei C; Pan P; Chen T; Zhang Y; Dai G; Tu J; Jiang Z; Zhao W; Shen J
Transl Androl Urol; 2021 Jun; 10(6):2435-2446. PubMed ID: 34295730
[TBL] [Abstract][Full Text] [Related]
44. [The diagnostic value of version 2.1 prostate imaging reporting and data system for prostate transitional zone lesions].
Yang S; Zhang CY; Zhang YY; Tan SX; Wei CG; Shen XH; Shen JK
Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3609-3613. PubMed ID: 33333685
[No Abstract] [Full Text] [Related]
45. Detection of Prostate Cancer Using Biparametric Prostate MRI, Radiomics, and Kallikreins: A Retrospective Multicenter Study of Men With a Clinical Suspicion of Prostate Cancer.
Montoya Perez I; Merisaari H; Jambor I; Ettala O; Taimen P; Knaapila J; Kekki H; Khan FL; Syrjälä E; Steiner A; Syvänen KT; Verho J; Seppänen M; Rannikko A; Riikonen J; Mirtti T; Lamminen T; Saunavaara J; Falagario U; Martini A; Pahikkala T; Pettersson K; Boström PJ; Aronen HJ
J Magn Reson Imaging; 2022 Feb; 55(2):465-477. PubMed ID: 34227169
[TBL] [Abstract][Full Text] [Related]
46. Diagnostic Accuracy and Interobserver Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers.
Wei CG; Zhang YY; Pan P; Chen T; Yu HC; Dai GC; Tu J; Yang S; Zhao WL; Shen JK
AJR Am J Roentgenol; 2021 May; 216(5):1247-1256. PubMed ID: 32755220
[No Abstract] [Full Text] [Related]
47. Impact of prostate MRI image quality on diagnostic performance for clinically significant prostate cancer (csPCa).
Cheng Y; Zhang L; Wu X; Zou Y; Niu Y; Wang L
Abdom Radiol (NY); 2024 Jun; ():. PubMed ID: 38935093
[TBL] [Abstract][Full Text] [Related]
48. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
49. Texture analysis based on PI-RADS 4/5-scored magnetic resonance images combined with machine learning to distinguish benign lesions from prostate cancer.
Ma L; Zhou Q; Yin H; Ang X; Li Y; Xie G; Li G
Transl Cancer Res; 2022 May; 11(5):1146-1161. PubMed ID: 35706813
[TBL] [Abstract][Full Text] [Related]
50. Performance variability of radiomics machine learning models for the detection of clinically significant prostate cancer in heterogeneous MRI datasets.
Gresser E; Schachtner B; Stüber AT; Solyanik O; Schreier A; Huber T; Froelich MF; Magistro G; Kretschmer A; Stief C; Ricke J; Ingrisch M; Nörenberg D
Quant Imaging Med Surg; 2022 Nov; 12(11):4990-5003. PubMed ID: 36330197
[TBL] [Abstract][Full Text] [Related]
51. Automated Patient-level Prostate Cancer Detection with Quantitative Diffusion Magnetic Resonance Imaging.
Zhong AY; Digma LA; Hussain T; Feng CH; Conlin CC; Tye K; Lui AJ; Andreassen MMS; Rodríguez-Soto AE; Karunamuni R; Kuperman J; Kane CJ; Rakow-Penner R; Hahn ME; Dale AM; Seibert TM
Eur Urol Open Sci; 2023 Jan; 47():20-28. PubMed ID: 36601040
[TBL] [Abstract][Full Text] [Related]
52. MRI-Based Radiomics Nomogram for Predicting Prostate Cancer with Gray-Zone Prostate-Specific Antigen Levels to Reduce Unnecessary Biopsies.
Zhang L; Zhang J; Tang M; Lei XY; Li LC
Diagnostics (Basel); 2022 Dec; 12(12):. PubMed ID: 36553012
[TBL] [Abstract][Full Text] [Related]
53. Radiomics Based on DCE-MRI Improved Diagnostic Performance Compared to BI-RADS Analysis in Identifying Sclerosing Adenosis of the Breast.
Ruan M; Ding Z; Shan Y; Pan S; Shao C; Xu W; Zhen T; Pang P; Shen Q
Front Oncol; 2022; 12():888141. PubMed ID: 35646630
[TBL] [Abstract][Full Text] [Related]
54. Predicting prostate cancer in men with PSA levels of 4-10 ng/mL: MRI-based radiomics can help junior radiologists improve the diagnostic performance.
Zhong JG; Shi L; Liu J; Cao F; Ma YQ; Zhang Y
Sci Rep; 2023 Mar; 13(1):4846. PubMed ID: 36964192
[TBL] [Abstract][Full Text] [Related]
55. Comparison of Prostate Imaging Reporting and Data System (PI-RADS) version 1 and version 2 and combination with apparent diffusion coefficient as a predictor of biopsy outcome.
Ryznarová Z; Keller J; Záleský M; Zachoval R; Čapek V; Malikova H
Neuro Endocrinol Lett; 2019 Mar; 40(1):41-50. PubMed ID: 31184822
[TBL] [Abstract][Full Text] [Related]
56. Deep-Learning Models for Detection and Localization of Visible Clinically Significant Prostate Cancer on Multi-Parametric MRI.
Sun Z; Wu P; Cui Y; Liu X; Wang K; Gao G; Wang H; Zhang X; Wang X
J Magn Reson Imaging; 2023 Oct; 58(4):1067-1081. PubMed ID: 36825823
[TBL] [Abstract][Full Text] [Related]
57. Combining prostate-specific antigen density with prostate imaging reporting and data system score version 2.1 to improve detection of clinically significant prostate cancer: A retrospective study.
Lei Y; Li TJ; Gu P; Yang YK; Zhao L; Gao C; Hu J; Liu XD
Front Oncol; 2022; 12():992032. PubMed ID: 36212411
[TBL] [Abstract][Full Text] [Related]
58. Improving the Early Detection of Clinically Significant Prostate Cancer in Men in the Challenging Prostate Imaging-Reporting and Data System 3 Category.
Morote J; Campistol M; Triquell M; Celma A; Regis L; de Torres I; Semidey ME; Mast R; Santamaria A; Planas J; Trilla E
Eur Urol Open Sci; 2022 Mar; 37():38-44. PubMed ID: 35243388
[TBL] [Abstract][Full Text] [Related]
59. Prebiopsy biparametric MRI: differences of PI-RADS version 2 in patients with different PSA levels.
Choi MH; Lee YJ; Jung SE; Rha SE; Byun JY
Clin Radiol; 2018 Sep; 73(9):810-817. PubMed ID: 29895386
[TBL] [Abstract][Full Text] [Related]
60. Three-dimensional convolutional neural network model to identify clinically significant prostate cancer in transrectal ultrasound videos: a prospective, multi-institutional, diagnostic study.
Sun YK; Zhou BY; Miao Y; Shi YL; Xu SH; Wu DM; Zhang L; Xu G; Wu TF; Wang LF; Yin HH; Ye X; Lu D; Han H; Xiang LH; Zhu XX; Zhao CK; Xu HX;
EClinicalMedicine; 2023 Jun; 60():102027. PubMed ID: 37333662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
